Epilepsy and Argininosuccinic Aciduria

Abstract

Background:

We have reviewed the occurrence of epilepsy in our patients with argininosuccinic aciduria (ASA) (OMIM 207900) and the possible relationship of late epilepsy to symptomatic seizures in the neonatal period, hyperammonaemia and treatments.

Methods:

We retrospectively analysed 11 ASA patients (8 neonatal onset and 3 late onset), 6 of whom had developed epilepsy.

Results:

Epilepsy in our sample was frequent (55%). It developed after a seizure-free period from the onset of the metabolic disease and seizures were responsive to treatment in all cases. Arginine plasma levels were kept in the same range for the 2 groups of patients with and without epilepsy.

Conclusions:

Although epilepsy is reported to be common among patients with ASA, very few long-term follow-up studies are available. The pathophysiological mechanism of epileptogenesis remains unclear. Neither hyperammonaemia nor acute symptomatic seizures at birth seem to be predictive of late epilepsy. Excessive arginine dosages as a cause of epilepsy could be reasonably excluded since our 3 late onset patients developed epilepsy before the diagnosis of ASA, at a time when they were likely to be arginine deficient. Arginine deficiency may not be excluded as cause of epilepsy, but further studies are needed to define its role.

Key words

argininosuccinic aciduria - epilepsy - seizures - urea cycle - arginine - creatine

• References

• 1 Arias A, Garcia-Villoria J, Ribes A. Guanidinoacetate and creatine/creatinine levels in controls and patients with urea cycle defects. Mol Genet Metab 2004; 82: 220-223
• 2 Ficicioglu C, Mandell R, Shih VE. Argininosuccinate lyase deficiency: Long term outcome of 13 patients detected by newborn screening. Molecular Genetics and Metabolism 2009; 98: 273-277
• 3 Gerrits GP, Gabreëls FJ, Monnens LA et al. Argininosuccinic aciduria: clinical and biochemical findings in three children with the late onset form, with special emphasis on cerebrospinal fluid findings of amino acids and pyrimidines. Neuropediatrics 1993; 24: 15-18
• 4 Gropman AL, Batshaw ML. Cognitive outcome in urea cycle disorders. Mol Genet Metab 2004; 81 (Suppl. 01) S58-S62
• 5 Leuzzi V. Inborn errors of creatine metabolism and epilepsy: clinical features, diagnosis and treatment. J Child Neurol 2002; 17: S089-S101
• 6 Lewis PD, Miller AL. Argininosuccinic aciduria: case report with neuropathological findings. Brain 1970; 93: 413-422
• 7 Mardach MR, Roe K, Cederbaum SD. Successful pregnancy outcome in a woman with argininosuccinate lyase deficiency. J Inherit Metab Dis 1999; 22: 102-106
• 8 Margalith D, Crichton JU, Wong L et al. Argininosuccinic aciduria. A developmental, biochemical case study. J. Neurol Sci 1983; 60: 217-233
• 9 Mercimek-Mahmutoglu S, Moeslinger D, Häberle J et al. Long-term outcome of patients with argininosuccinate lyase deficiency diagnosed by newborn screening in Austria. Mol Genet Metab 2010; 100: 24-28
• 10 Moser HW, Efron ML, Brown H et al. Argininosuccinic aciduria. Report of two new cases and demonstration of intermittent elevation of blood ammonia. Am J Med 1967; 42: 9-26
• 11 Newnham T, Hardikar W, Allen K et al. Liver transplantation for argininosuccinic aciduria: clinical, biochemical, and metabolic outcome. Liver Transpl 2008; 14: 41-45
• 12 Parsons HG, Scott RB et al. Argininosuccinic aciduria: long term treatment with arginine. J Inherit Metab Dis 1987; 10: 152-161
• 13 Scaglia F, Brunetti-Pierri N, Kleppe S et al. Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism J Nutr 2004; 134: 2775S-2782S
• 14 Shindo S, Mori A. Metabolism of L-amidino-¹⁵N-arginine to guanidine compounds. In: Mori A, Cohen BD, Lowenthal A. (Eds) Guanidines. New York: Plenum Press; 1985: 71-81
• 15 Schutgens RB, Beemer FA, Tegelaers WH et al. Mild variant of argininosuccinic aciduria J Inherit Metab Dis 1980; 2: 13-14
• 16 Schultze A, Ebinger F, Rating D et al. Improving treatment of guanidinoacetate methyltransferase deficiency: reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation. Mol Genet Metab 2001; 74: 413-419
• 17 Sewell AC, Böhles HJ, Herwig J et al. Neurological deterioration in patients with urea cycle disorders under valproate therapy − a cause for concern. Eur J Pediatr 1995; 154: 593-594
• 18 Thakur V, Rupar CA, Ramsay DA et al. Fatal cerebral edema from late-onset ornithine transcarbamylase deficiency in a juvenile male patient receiving valproic acid. Pediatr Crit Care Med 2006; 7: 273-276
• 19 Van Spronsen FJ, Reijngoud DJ, Verhoeven NM et al. High cerebral guanidinoacetate and variable creatine concentrations in argininosuccinate synthetase and lyase deficiency: implications for treatment?. Mol Genet Metab 2006; 89: 274-276
• 20 Widhalm K, Koch S, Schebeinreiter S et al. Long term follow-up of 12 patients with the late onset variant of argininosuccinic acid lyase deficiency: no impairment of intellectual and psychomotor development during therapy. Pediatrics 1992; 89: 1182-1184